Role of rs7903146 polymorphism and adropin serum level in patients with diabetes mellitus; a case–control study from Isfahan, Iran

Abstract

Background

Type-2 diabetes mellitus (T2DM) is the common endocrinopathy which characterised by insulin resistance, insufficient expression or secretion of insulin and decrement of insulin effectiveness. Although T2DM has unknown aetiology, the strongest susceptible gene in this disease is TCF7L2. Adropin peptide may have roles in T2DM pathogenesis due to several roles in glucose tolerance, decrement of insulin resistance, lipid metabolism and energy homoeostasis.

Aim

To evaluate the serum level of adropin in T2DM patients and comparing with healthy individuals as well as assessing frequency of rs7903146 genotypes/alleles in patients and control groups.

Methods

We analysed the frequency of rs7903146 genotypes/alleles in 93 patients with T2DM disease and 53 healthy individuals by the method of polymerase chain reaction–restriction fragment length polymorphism analysis. The serum level of adropin was measured by using enzyme-linked immunosorbent assay technique.

Results

The mean serum level of adropin was 12.32 ± 2.98 and 9.51 ± 2.73 in patients and control groups, respectively (p value < .001). Also, there were significant difference in frequency of genotypes and alleles of rs7903146 in patients and controls groups (p < .001). The rs7903146T/T and rs7903146C/T genotypes increased risk of T2DM disease (OR: 6.035 and OR: 3.082, respectively). Interestingly, the highest level of adropin was detected in T2DMpatients with rs7903146T/T genotype.

Conclusion

Our analysis showed higher level of adropin in T2DM patients and increased risk of T2DM with rs7903146T/T and rs7903146C/T genotypes.

Keywords:

• Diabetes mellitus
• adropin
• single nucleotide polymorphism
• rs7903146
• TCF7L2
• ELISA

Acknowledgment

This study was finanacialy supported by Isfahan University of Medical Sciences. The authors would like to thanks Padginteb company for their kind helps in providing ELISA kit of adropin hormon. Also we thanks Mercedeh Hosseini for her technical helps in data analysis.

Disclosure statement

The authors have no conflict of interest to report.